ARVN - アルビナス (Arvinas Inc.)

ARVNのニュース

   Arvinas Inc. (NASDAQ:ARVN)’s 12-Month Price Target Currently Stands At $170.00  2022/04/09 12:30:00 Marketing Sentinel
In last trading session, Arvinas Inc. (NASDAQ:ARVN) saw 0.44 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $66.42 trading at -$3.74 or -5.33% at ring of the bell on the day assigns it a market valuation of $3.39B. That closing price of ARVN’s stock is at … Arvinas Inc. (NASDAQ:ARVN)’s 12-Month Price Target Currently Stands At $170.00 Read More »
   Expert Ratings For Arvinas  2022/04/06 18:10:52 Benzinga
Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 0 0 0 0 These 6 analysts have an average price target of $102.33 versus the current price of Arvinas at $70.83, implying upside. Below is a summary of how these 6 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts … Full story available on Benzinga.com
   Is Arvinas Inc. (NASDAQ: ARVN) A Good Pick For New Investors Now?  2022/04/02 13:30:00 Stocks Register
Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 04/01/22, with the stock price up by 4.04% to the previous day’s close as strong demand from buyers drove the stock to $70.02. Actively observing the price movement in the last trading, the stock closed the session at $67.30, falling within a range of $67.40 and … Is Arvinas Inc. (NASDAQ: ARVN) A Good Pick For New Investors Now? Read More »
   Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN)  2022/03/12 13:30:00 Stocks Register
Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.53% to the previous day’s close as strong demand from buyers drove the stock to $68.21. Actively observing the price movement in the last trading, the stock closed the session at $68.57, falling within a range of $67.685 and … Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN) Read More »
   Where Arvinas Stands With Analysts  2022/03/01 14:09:59 Benzinga
Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Arvinas has an average price target of $114.0 with a high of $157.00 and a low of $91.00. Below is a summary of how these 4 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … Full story available on Benzinga.com
   Arvinas Inc Ranked Among Todays Top Shorts Amid Lower-Than-Expected New Jobs  2021/09/03 17:14:52 Bitcoin Ethereum News
The post Arvinas Inc Ranked Among Todays Top Shorts Amid Lower-Than-Expected New Jobs appeared on BitcoinEthereumNews.com . Getty Thursdays jobless claims impressed. They came in at a pandemic-era low of 340,000 and crushed the forecasted 345,000. Both the S&P and Nasdaq NDAQ hit new records. Friday, however,
   Arvinas to Participate in Upcoming Virtual Investor Conferences  2021/09/01 11:00:00 Intrado Digital Media
NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences:
   Arvinas Inc Ranked Among Todays Top Shorts  2021/08/10 18:52:42 Bitcoin Ethereum News
The post Arvinas Inc Ranked Among Todays Top Shorts appeared on BitcoinEthereumNews.com . getty Stocks saw minor gains on Tuesday that were capped by more fears of the Delta variant throwing a serious wrench into the economic recovery and reopening. The Dow Jones
   Arvinas and Insilico Medicine ink R&D collaboration agreement  2021/08/09 13:26:19 Seeking Alpha
   Arvinas EPS misses by $0.17, beats on revenue  2021/08/05 11:55:22 Seeking Alpha
   Arvinas Inc (ARVN) President and CEO John G Houston Sold $3.6 million of Shares  2021/06/12 19:15:11 GuruFocus
Related Stocks: ARVN ,
   Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven  2021/06/07 21:19:00 GlobeNewswire
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today joined state and local officials, fellow tenants, and community partners, in a groundbreaking ceremony for 101 College Street, a new 525,000-square-foot-building to be constructed as part of New Havens Downtown Crossing revitalization project. Arvinas will lease three of the 10 floors at 101 College and this space will serve as the Companys headquarters beginning in 2024.
   Progressive Supranuclear Palsy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect and Others  2021/06/04 03:04:02 AB Newswire
   Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference  2021/06/03 00:00:00 BioSpace
Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Ron Peck, M.D., Chief Medical Officer, and Sean Cassidy, Chief Financial Officer, will participate in a fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Thursday, June 10 at 10:30 a.m. ET.
   Arvinas Stock Pops On Buy Rating As Biotech Takes On ''Undruggable Targets''  2021/05/21 16:10:02 Investor''s Business Daily
Arvinas'' bid to wrangle "undruggable targets" could reap $4 billion in sales, an analyst said. ARVN stock popped on her rating.

calendar